Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds
Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds Signaling Molecule IL-38 Can Reduce Inflammation, May Be Therapy Target, Study Finds
Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests
Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests Arginase 1 Protein May Protect from Sjögren’s-related Dryness, Mouse Study Suggests
Ask the Expert: CBD Oil and Sjögren’s
https://www.sjogrens.org/blog/2020/ask-the-expert-cbd-oil-and-sjogrens Ask the Expert: CBD Oil and Sjögren’s Ask the Expert, Symptoms, Treatment — Aug 12, 2020
OMRF needs participants for Sjögren’s Syndrome study
https://kfor.com/news/local/omrf-needs-participants-for-sjogrens-syndrome-study/ OMRF needs participants for Sjögren’s Syndrome study
University of Queensland and CSL Limited partner up to progress treatments for Sjogren’s syndrome
https://www.uq.edu.au/news/article/2020/07/partnership-progress-treatments-sjogren%E2%80%99s-syndrome Partnership to progress treatments for Sjogren’s syndrome The University of Queensland and global biotechnology company CSL Limited
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy for Sjogren’s
Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy Luminary Therapeutics, Case Western Team Up to Develop New CAR T-Cell Therapy
Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding
https://www.ucsf.edu/news/2020/07/418091/two-projects-using-hydrogel-biomaterials-stimulate-tissue-regeneration-move Two Projects Using Hydrogel Biomaterials to Stimulate Tissue Regeneration Move Forward with New Funding
Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome
https://www.einnews.com/pr_news/521168729/luminary-therapeutics-and-case-western-reserve-university-enter-formal-collaboration-for-development-of-baff-car Luminary Therapeutics and Case Western Reserve University enter formal collaboration for development of BAFF CAR-T (LMY-920) for Sjogren’s Syndrome Luminary Tx and CWRU enter formal collaboration for clinical development of novel BAFF CAR to treat Mantle Cell Lymphoma and Sjogren’s Syndrome MINNEAPOLIS, MN, USA, July 7, 2020 /EINPresswire.com/ — Luminary Therapeutics (Luminary Tx) and […]
Study identifies CP-25 as a potential drug for the treatment of primary Sjögren’s syndrome
New research published in Nature’s Laboratory Investigation shows that CP-25 “increased saliva flow, alleviated the salivary gland indexes, and improved tissue integrity” in a mouse model of primary Sjogren’s syndrome. Researchers “identified the underlying mechanisms of the therapeutic effect of CP-25 and provided an experimental foundation for CP-25 as a potential drug in the treatment […]
How the Hydroxychloroquine (HCQ) Shortage Highlights Sjogren’s Neglect
https://www.sjogrensadvocate.com/post/hcq-i-the-shortage How the hydroxychloroquine (HCQ) shortage highlights Sjogren’s neglect Updated: 4 hours ago
The 2020 Sjögren’s Foundation National Patient Conference (June 26 & June 27, 2020) is going Virtual
https://www.sjogrens.org/news/2020/the-2020-sjogrens-foundation-national-patient-conference-is-going-virtual The 2020 Sjögren’s Foundation National Patient Conference is going Virtual! June 26 & June 27, 2020
Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
https://www.biospace.com/article/releases/wize-pharma-completes-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogren-s-syndrome/ Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndrome
Targeted Approach for Tackling Sjögren’s Syndrome – Small molecules restore salivary function in mice
https://www.nidcr.nih.gov/news-events/nidcr-news/targeted-approach-tackling-sjogrens-syndrome Targeted Approach for Tackling Sjögren’s Syndrome Small molecules restore salivary function in mice
Abatacept Fails Clinical Trial for Sjögren’s Syndrome
https://www.rheumatologynetwork.com/sjogrens-syndrome/abatacept-fails-clinical-trial-sjgrens-syndrome Abatacept Fails Clinical Trial for Sjögren’s Syndrome
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled Phase 4 Trial of Treatment for Dry Eyes, LO2A Drops, in Sjögren’s Patients Fully Enrolled
Wize Pharma Completes Patient Enrollment In Phase 4 Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome
https://www.prnewswire.com/news-releases/wize-pharma-completes-patient-enrollment-in-phase-iv-study-of-lo2a-for-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome-300990264.html Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren’s Syndrome – Topline Results Expected Q2 2020 – Study designed to support approval pathway in the U.S. and other major markets Jan 21, 2020, 09:00 ET HOD HASHARON, Israel, Jan. 21, 2020 […]
Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers
Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers Potential Sjogren’s Therapy LOU064 Shows Promise in Early Lab Studies, Healthy Volunteers
Hope for patients with rare Sjögren’s syndrome
https://medicalxpress.com/news/2019-10-patients-rare-sjgren-syndrome.html Hope for patients with rare Sjögren’s syndrome
The Challenge of Identifying Sjogren’s Syndrome
The Challenge of Identifying Sjogren’s Syndrome The main symptoms — dry eyes and mouth, fatigue and limb pain — are common complaints associated with any number of health problems.
AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s
AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s AT-RvD1 Restores Function of Salivary Glands, Decreases Harmful T-cells in Mouse Model of Sjögren’s